The safety label for the smoking cessation drug Chantix (varenicline) has been updated to include new warnings about cardiovascular risks. The warning is based on a large, combined analysis of clinical trials that showed more serious cardiovascular events occurred in people who were taking Chantix. The report was released late last year by the Food and Drug Administration (FDA), which added that the risks were uncommon in both the Chantix and placebo groups, and that it is difficult to determine whether the excess risk of serious heart events among patients taking Chantix was due to the drug or simply chance. ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.